A Phase 3 interventional study of Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111) and Placebo in Pain, sponsored by Bayer. Completed at 19 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-08.
Sponsored by Bayer · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.
Among the 25 studies testing naproxen in Pain, this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 3, and was the 5th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:
American University of Beirut Medical Center · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 326 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
14 studies in Pain by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 14 studies in Pain by Bayer, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 3rd registered.
Bayer’s Pain studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing naproxen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 14 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to placebo (capsules containing no drug) when taken for 10 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)
Drug: Placebo
Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product
Please see further details in Adverse Events (AE) section
Time frame: 10 days after randomization
Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product
Please see further details in AE section
Time frame: 10 days after randomization
Percentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product
Time frame: 10 days after randomization
Treatment Compliance - Number of Capsules Taken
Time frame: 10 days after randomization
Treatment Compliance - Duration of Exposure to Treatment in Days
Time frame: 10 days after randomization
| Milestone | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo |
|---|---|---|
| Started | 217 | 109 |
| Completed | 213 | 105 |
| Not completed | 4 | 4 |
| Withdrew: Adverse event | 4 | 4 |
| Percentage of participants | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo |
|---|---|---|
| Percentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product | 1.8 | 3.7 |
Please see further details in Adverse Events (AE) section
| Percentage of participants | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo |
|---|---|---|
| Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product | 39.6 | 45.0 |
Please see further details in AE section
| Percentage of participants | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo |
|---|---|---|
| Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product | 0 | 0 |
| Capsules | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo |
|---|---|---|
| Treatment Compliance - Number of Capsules Taken | 20.1 ± 1.73 | 19.9 ± 2.98 |
| Days | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo |
|---|---|---|
| Treatment Compliance - Duration of Exposure to Treatment in Days | 9.9 ± 0.76 | 9.8 ± 1.37 |
Collected over Treatment emergent adverse events (TEAEs) were collected from the date of the first dose of study drug in the treatment period for 12 days, or for 30 days after the last study drug administration if they were serious adverse events (SAEs).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | — | 0/217 (0%) | 86/217 (39.6%) |
| Placebo | — | 0/109 (0%) | 49/109 (45%) |
| Event | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo |
|---|---|---|
| HEADACHENervous system disorders | 23/217 | 21/109 |
| SOMNOLENCENervous system disorders | 10/217 | 4/109 |
| NAUSEAGastrointestinal disorders | 9/217 | 1/109 |
| DIZZINESSNervous system disorders | 9/217 | 0/109 |
| BACK PAINMusculoskeletal and connective tissue disorders | 8/217 | 3/109 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 0/217 | 4/109 |
| DIARRHOEAGastrointestinal disorders | 7/217 | 2/109 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 3/217 | 3/109 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 4/217 | 3/109 |
| ABDOMINAL DISCOMFORTGastrointestinal disorders | 5/217 | 2/109 |
| Age, Continuous(years) | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo | Total |
|---|---|---|---|
| Mean | 46.9 ± 18.14 | 47.1 ± 19.26 | 47.0 ± 18.49 |
| Age, Customized(Participants) | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo | Total |
|---|---|---|---|
| <60 years | 152 ± 70.0 | 72 ± 66.1 | 224 |
| Greater than or equal to 60 years | 65 ± 30.0 | 37 ± 33.9 | 102 |
| >65 years | 46 ± 21.2 | 28 ± 25.7 | 74 |
| Sex: Female, Male(Participants) | Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111) | Placebo | Total |
|---|---|---|---|
| Female | 133 | 65 | 198 |
| Male | 84 | 44 | 128 |
The record gives a start of May 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 11 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen